Hello, and welcome to the Q3 2026 results presentation for BioSyent Inc. My name is René Goehrum, and I am the President and CEO of the company. Before I get going with today's presentation, I just want to bring your attention to our forward-looking statements disclaimer, and also to confirm to you that currencies referred to in this presentation are Canadian dollars unless we specify otherwise. If you are new to the BioSyent story or have been following us for a while and have observed some changes in our business, I thought I might start today's presentation with a confirmation of the business purpose, and how we operate. BioSyent brings proven, differentiated, innovative healthcare products to patients and their providers. We do this through two commercial platforms, one in specialty pharmaceuticals and one in oral health products.
We operate from a base in Canada, where over 90% of our revenue is generated, but we also have revenue that is generated from customers outside of Canada. At this stage, our oral health business does not yet have revenue from outside of Canada, but that certainly is part of our go-forward strategy. Glimpse at our new brand wall, and I will dive into the presentation with a look at our Q3 sales. Overall, we achieved just under CAD 20.1 million in revenue for Q3. That compares favorably to CAD 12.2 million last year. Of note, we acquired Oral Science on March 1st , 2026, so this number is obviously influenced by that. This is now the second full quarter where we have business performance from our oral health segment.
In Q1, we reported one month of oral health revenue, in Q2, three full months in the quarter, and this Q3, three full months in the quarter. Overall, the oral health business obviously is the most significant contributor to the revenue growth for obvious reasons. In the box, just to draw your attention down on the bottom left of the screen, you will see a comparison of the oral health business, 2026 versus 2025. That is up 10%.
J ust to emphasize to you that we did not own the business in the year ago period. We are just giving that for some context. Let' s go a little bit deeper into the financials. As I mentioned, revenue of CAD 20 million. Far right of your screen in the green box is the most recent quarter, Q3 2026. That represented growth of 64%. Our EBITDA was just under CAD 5.6 million.
Our net income after tax, just under CAD 2.9 million, CAD 0.25 a share on a fully diluted basis for the quarter, and return on equity of 23%. In all cases, improvement over a year ago, and you can see here the trend back to Q3 of 2024. Just one other thing that I would like to mention here is the significant growth in revenue and EBITDA in comparison to more modest growth on net income after tax.
If you are new to the story, you will not have seen this in prior months, and I would say that the operating cash flow of the business looks more like the EBITDA figure. In fact, our operating cash flow for the quarter was about CAD 6 million. If you adjust that for tax, about CAD 4.5 million. Significant growth versus previous year.
We are depreciating the intangible assets acquired in the Oral Science acquisition, and that has some impact on the net income after tax. I will have a little bit more on a balance sheet look later on in the presentation. On a year-to-date basis, so nine months now to September 30, you see CAD 54 million in revenue, up 61% to the year ago. EBITDA of CAD 14.2 million, net income after tax of just over CAD 8 million, and earnings per share of CAD 0.70.
Same comments I had about net income after tax, percentage change versus revenue and EBITDA flow through into our net income after tax calculation. These nine months were two months at the start of the year where we were operating without the acquisition of Oral Science, and then now seven months in these of the nine months we are showing you here include Oral Science.
Our fully diluted earnings per share reached CAD 0.87 on a trailing 12-month basis. Looking back, CAD 0.87. I have already mentioned CAD 0.25 for the quarter itself. Q3 2026 represented our 65th consecutive profitable quarter, and essentially both revenue and earnings growth and our NCIB have been driving the impact on earnings per share. Without buybacks dating all the way back to 2018, and that is when we started, our earnings per share would be in the CAD 0.68 range.
That is enhanced by CAD 0.19 through our buyback, a value-enhancing activity. I have mentioned the acquisition of Oral Science, obviously, to walk you through the financial performance of the business. Just a couple of comments here. As a reminder, we acquired Oral Science on March 1st. We paid just under 6x EBITDA, that is based on the EBITDA of the business in 2025.
This worked out to a CAD 25.5 million purchase price. We had agreed that we would pay up for excess working capital. In addition to the CAD 6.3 million of inventory receivables and cash that was in the business, there was an extra CAD 1.85 million we paid for that as well. In the deal, there is a performance earn-out based on the profitability of the business over a two-year period, so ending in 2026. We expect that that performance earn-out will be completed and paid out by the end of Q1, maybe at the beginning of Q2. We also have an obligation to pay a royalty on one product going into the future. It is capped at a certain dollar amount and also capped in time. I mentioned a balance sheet look.
In the earnings, you will see amortization expenses for Q3 of CAD 825,000, and on a year-to-date basis of just over CAD 1.9 million. We are amortizing the acquired intangible assets. That is why you see an additional expense on amortization, and then obviously that flows through on net income after tax. How do we grow from here? I have mentioned that we have a pharmaceutical platform and specialty pharmaceuticals.
We have got an oral health platform now with Oral Science. We have every intention of continuing to invest in organic growth in both of those platforms. Essentially, it gives us more areas to deploy capital, both into in-licensing and M&A, and we intend to expand both our in-Canada and our ex-Canada business for the oral health segment. That will mean new business, new revenue coming from customers outside of Canada.
Couple things to touch on in terms of highlights on a year-to-date basis. If you are not aware, we are a dividend payer. We have been paying CAD 0.055 a share in dividends. We will have declared our upcoming dividend payable in December at CAD 0.055 a share. That is a 10% increase over the year ago and represents a three-year compound annual growth rate on the dividend of 11%. This year, on a year-to-date basis, we have repurchased just over 326,000 shares, canceled them under our NCIB.
We continue to look for opportunities to deploy capital into buybacks. That will be an important part of our capital allocation approach as we move forward. FeraMAX, our oral iron supplement, was named the number one recommended supplement in Canada for now the 11th consecutive year. This is amongst pharmacists and doctors across Canada. Health Canada approved our THYCONVI product.
Just a couple of comments on that in a moment. That was approved in May. In September this year, The Globe and Mail Report on Business named us as one of Canada's top growing companies. I mentioned Health Canada has approved our levothyroxine product, THYCONVI. This is a liquid levothyroxine product that is the first and only such liquid levothyroxine in Canada. This is a synthetic hormone for hypothyroidism, and our product addresses issues that both healthcare professionals and patients have, challenges for some patients around tablet administration, dosing flexibility, and this just makes the administration of this drug much more convenient for a subset of patients in the Canadian market. This is a Canada-only launch. We will be launching it in the first quarter of 2027. I have already mentioned FeraMAX being the number one recommended.
This has really been a key foundation of our business and our cash generation and how we are then deploying that capital into expanding our product portfolio, and of course, subsequently now deploying capital into acquisitions that further broaden the base of business that we have and our growth opportunities. As we look forward to what we look at as our growth drivers in the business, the THYCONVI launch will be important for us. The oral health business is a good business. We bought a good business with good people, great brands, and a really well-established footprint in the Canadian market, and we see opportunities to continue to grow that business at a double-digit pace into the future. Of course, adding to that by selling the brands that we own, X-PUR and PerioMonitor, to customers outside of Canada.
We see a couple of growth avenues from the existing portfolio of products, and we are working on adding additional assets into that portfolio that we will see market in 2027 and beyond. We have been working a lifecycle strategy on the FeraMAX business. We have a new product that is under development for a new use case. That will be a 2028 launch. We are working on further expanding distribution of FeraMAX outside of Canada, and there will be more on that as we roll into 2027. Of course, when you are traditionally not an R&D company, acquisition and in-licensing is core to our strategy. It is the lifeblood of a health products business, and that is a non-stop, always on-the-go activity, both in acquisition and in licensing.
We are working on opportunities in both of those areas, and simply, that is now expanded to not just include specialty pharmaceutical, but also our oral health business. I have a couple of comments about the landscape around geopolitics, trade, and the economy. Not a lot has changed over the last three months or so since we last reported to you. It is an interesting mix, combination of armed conflicts which persist.
We are not at all fooled into being complacent around those armed conflicts and their potential impacts on our business. For us, that is mostly in the Middle East, but there is also an ongoing tariff and counter-tariff situation for Canada vis-à-vis the United States. At the recording of this presentation, nothing resolved, and I don't expect there to be anything resolved in the near term on that topic. We are keeping our eye on it.
We have, at this point in time, not been impacted by tariffs, counter-tariffs, and we don't expect in the near term to be so impacted. I guess going forward, generally, the inflationary impacts of the geopolitical situation and tariffs, and monitor carefully the impacts on transportation, our supply chains, our cost of goods. There has been some inflationary pressure. We have been carefully managing our inventory levels so that we can mitigate those impacts going into 2027.
In the first several quarters, we don't see a negative impact from inflation, but certainly, like other businesses, we are seeing inflationary pressure on the business. The last one that I want to comment on is just consumer behavior. I am going to start with the Canadian consumer, as 90% or more of our revenue comes from the Canadian market for both pharma and oral health combined.
Although the Canadian economy has held up, I would say, surprisingly well, given the tariff and inflationary situation, I would say that we don't take that for granted and are not complacent about it, and we are concerned over time that perhaps certain elements or segments of the Canadian consumer population may trade down. BioSyent and Oral Science together, we are selling, promoting products that are premium-priced products that solve a problem for patients and consumers and their healthcare providers. We are in the premium-priced branded business, and there is always a risk that the consumer trades down. I commented about balance sheet earlier. When we acquired Oral Science, we took on CAD 8 million of short-term debt. You see here in the middle column, March 1st , 2026, CAD 8 million in short-term debt.
I reported with the financial statements and MD&A that you will see that are associated with my presentation today, you will see CAD 2 million of short-term debt as of September 30th. Actually, we initiated the transaction to pay off that debt in September. It did not hit the bank statements until October 1st. As of October 1st, subsequent to the end of the quarter, the debt was fully repaid.
The debt balance now, as I record this presentation, is zero with respect to the short-term acquisition debt that we took down for the Oral Science acquisition. We expect our cash position to return to the range of where it was prior to the Oral Science acquisition by the end of 2027, and we are not waiting for that point in time before we start looking for additional acquisition opportunities.
I think we've demonstrated to the market that we will be patient and we will look for the right opportunities that make the most sense for us to deploy capital that we think we can grow businesses and earn a good return on that investment. I've used this slide now for years in articulating what our approach was to capital allocation. The most important thing to know is that we think of our capital allocation with respect to our strategy, and that is essentially to grow revenue, grow profit, diversify our business, and operate our business with every intention of being in business for a long time, so corporate longevity. The first dollar of cash or free cash that we generate, we think of how to deploy that into growth in the business and diversification.
The reality is that we have a capital-light business model. The acquisition of Oral Science really didn't change that. The Oral Science business model is also capital-light in nature. We're not in the manufacturing business. We don't have bricks and mortar in the conventional sense. We use contract manufacturing. Our supply partners manufacture. We generate considerable free cash flow, which we have been investing in launching new brands in pharma and in oral health.
We've also deployed capital into the acquisition of Tibelia Global that was executed in September of 2024, and we paid just under five times multiple for that business. We've already spoken about the acquisition of Oral Science at a less than six times multiple. We are in a position to deploy capital in acquisition, in licensing, launching products, and yet our business is generating sufficient cash to do all of those things.
We are a dividend payer, and we have every intention to continue allocating capital into dividends. We do buy back shares, and we have consistently repurchased shares going back to the fourth quarter of 2018. We did, and if you go back and look at our recent history, you'll see that that activity was significantly less in 2025 than we had bought back shares in both 2026 and prior to 2025, and that's simply because we were working on the Oral Science deal, and we were keeping some powder dry until we had more clarity around that deal. We see share buybacks being a core part of our mix of capital allocation as we move forward.
I often put this slide up towards the end of a presentation, mostly to draw to your attention that we have discontinued the use of share options as an element of management and board equity compensation, and we pivoted to the use of restricted share units. This was done in 2019, so no new share options have been issued in BioSyent for over seven years. There are some options still outstanding. They are running off here in the next couple of years. In essence, what we do with the RSUs is we go into the market and buy BioSyent shares and hold them in trust to fulfill our obligations in the future under our RSU program. You can see here, the shares held in trust fairly closely emulate the shares that we've got outstanding in our RSU program.
A pretty non-dilutive approach to our compensation and equity compensation program, and that is because 27% of our company is owned by insiders. We think like owners and manage our cap table accordingly. I wanted to thank you for your continued interest, and in the case of owners of BioSyent, your ownership of BioSyent and your confidence in us as stewards of your capital, and we look forward to reporting continued development of the business and execution against our growth opportunities. Thank you.